The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...

Lymphoma causes symptoms of organ failure before death. Learn what patients in palliative or hospice care could experience ...

FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) ...

A regulatory decision on odronextamab for R/R FL is expected by July 30, 2025. The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Beyond research, Germain concludes the conversation by providing helpful insights into the biggest challenges in lymphoma ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.